Zulresso™ (brexanolone injection)

Zulresso (brexanolone) is covered only for moderate-to-severe postpartum depression in patients ≥15 years who are ≤6 months postpartum with symptom onset in the third trimester or within 4 weeks post‑delivery; patients who are currently pregnant, >6 months postpartum, with onset outside that window, or with less-than-moderate severity are excluded. Approval is limited to one 60‑hour IV infusion at 90 mcg/kg/hour per postpartum period and requires documentation of diagnosis, severity and timing, delivery date, pregnancy status, age, prescriber or consult with a psychiatrist/OB‑GYN, and infusion details.

"Treatment of postpartum depression (PPD) in adults (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.